Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...

Key Takeaways Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup.The deal values Verve at about $1.3 billion, with some of Eli Lilly's ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk By Eli Lilly and Company, Verve Therapeutics, Inc. Jun 17, 2025 Updated Jun 17, 2025 1 of 2 ...

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston -based clinical-stage company developing genetic medicines for ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston -based clinical-stage company developing genetic medicines for ...